XNAS · MBRX
+2.53% · +$0.0600 · Vol 120.3K
Market closed · last close 4:00 PM ET · price as of 18:03:56 ET
Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

PHARMACEUTICAL PREPARATIONS
$2.43
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is MBRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for MBRX are being assembled.
About Moleculin Biotech, Inc.
PHARMACEUTICAL PREPARATIONS
Listed since
2016
Employees
17
Country
US

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.33
Day high
$2.48
Day low
$2.33
Previous close
$2.37
52W high
$3.42
-28.98% from high
52W low
$2.31
11% of range
Market cap
$16.7M
EPS
$-3.5400
Shares out
7.1M
Volume
120.3K
VWAP
$2.42
Price history computed in-house
1W
-3.19%
1M
-9.35%
SMA 50 $2.76 · below
SMA 200 $2.76 · below
52W position 11%
Veridion warehouse edge

Warehouse intelligence for MBRX.

Veridion Score
46
0: 941: 262: 503: 104: 785: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

MBRX insider activity

Moleculin Biotech, Inc.

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for MBRX.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

MBRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for MBRX in this window.
Lobbying spend

MBRX lobbying filings, year to date.

Registered lobbying filings matched to Moleculin Biotech, Inc..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for MBRX in this window.
Latest news · MBRX
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for MBRX.
Options
Sovereign unlock shows live options positioning for MBRX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.